GSK Acquires Syndivia's Prostate Cancer ADC
GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for prostate cancer treatment.
Despite having its own ADC in development for prostate cancer, GSK is expanding its portfolio in this area, fueling industry buzz for the promising anti-tumor modality.
The deal is worth £268m, demonstrating GSK's commitment to the modality.
The gold standard of business intelligence.
GSK's move combines business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Author's summary: GSK buys Syndivia's prostate cancer ADC for £268m.
More News
- Should you start or sit Justin Jefferson vs. Commanders?
- Synonyme und Antonyme von elaborate auf Englisch
- Hudson’s Bay Stripes Return at Canadian Tire in Limited Capsule
- Hudson’s Bay Downtown Vancouver Store for Sale
- ‘Happy Holidays’ Review
- Jefferson boys wrestling beats rival Alameda in pin-fest
- Joe Perry Sheds New Light on the Future of Aerosmith
- Hunt: Showdown Elaborates On Upcoming Player Profiles In Update 2.6
- Thomas Jefferson University Overview
- [JEFFERSON PARISH LANDFILL DROP-OFF SITE CLOSED TO PUBLIC FOR REMAINDER OF THE DAY]